Project Grant R01DK142985
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $422K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts Institute of Technology $518,779 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Listing Project Grant R01DK145857). The award funds research to define the molecular signals that drive liver regeneration following injury. The work investigates how the body senses liver injury and stimulates hepatocyte proliferation, with focus on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $3.517 million on September 4, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate induced pluripotent stem cell-derived endothelial cell therapy for liver disease. The research will assess the therapeutic potential of iPSC-derived endothelial cells to promote liver regeneration and alleviate liver disease. The approach...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $814,500 to the University of Pittsburgh on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research dissecting functional decompensation of end-stage liver disease and investigating the mechanism and impact of transcription factors on long-term functional reprogramming. The research examines how the transcription factor HNF4A—which controls...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts Institute of Technology $100,228 on May 1, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and apply synthetic biology tools to engineer vascularized human liver tissues capable of dynamically responding to regenerative stimuli. The project establishes closed-loop synthetic gene circuits regulating proangiogenic and hepatoprotective growth...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Trustees of Boston University $100,228 on February 1, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the therapeutic potential of induced pluripotent stem cell–derived endothelial cell (IEC) therapy for promoting liver regeneration in acute liver injury. The research will establish protocols for generating pure populations of iPSC-derived endothelial...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $584,232 to Renovate Biosciences Inc. on September 25, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Renovate Biosciences will generate human livers from donor patient-specific cells using pigs as bio-incubators. Following technical validation, the work will establish a pathway for producing on-demand transplantation-ready hepatocytes for cellular therapies and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Virginia Commonwealth University $352,242 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of the transcription factor RUNX1 in cholangiocyte signaling and biliary fibrosis. The project will examine how RUNX1 coordinates transcriptomic and lipidomic programs in cholangiocytes activated by transforming growth factor-beta, with...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Virginia Commonwealth University $134,728 on December 12, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate hepato-skeletal crosstalk in metabolic dysfunction-associated steatotic liver disease (MASLD)-associated fracture susceptibility. The research uses the diet-induced animal model of NAFLD (DIAMOND) mouse to elaborate histologic bone changes and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $676,279 to The University of Texas Southwestern Medical Center on January 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify metabolic regulators of hepatic phosphatidylcholine synthesis. The research addresses genetic regulation of phosphatidylcholine (PC) metabolism in response to metabolic stress and its relevance to metabolic dysfunction-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $158,220 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of neutrophil-derived HIF1A signaling in hepatic ischemia/reperfusion injury. The research addresses mechanisms of graft dysfunction following liver transplantation, a leading cause of poor outcomes in end-stage liver...